Biotech Values

[mcbio]

FGEN -

Manufacturing for Pam is going to require a massive investment. But maybe that's why they need to partner.

Very clear reference by Neff during the CC of wanting to combine pamrevlumab with a PDL1 (in oncology). So, I wonder if that pushes those with a PDL1 to the top of the list of likely partners. And of those with a PDL1, I wonder if Roche is perhaps the most likely given that they have a key PDL1 and I believe also have a broad fibrotic focus. (If just PD-1 would suffice and doesn't have to be PDL1, then I would certainly think of BMY as well but Neff very specifically referenced PDL1.)